KLARK KENT: Open Payments
NPI 1659762144 · TEXARKANA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$880 in 30 payments from 9 companies in 2025. Trend: 2023 $668 · 2024 $839 · 2025 $880
Food & beverage: $880
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 10 | $335 |
| ViiV Healthcare Company | 10 | $231 |
| Lilly USA, LLC | 1 | $103 |
| Merck Sharp & Dohme LLC | 2 | $54 |
| ABBVIE INC. | 2 | $50 |
| Exact Sciences Corporation | 2 | $44 |
| Novo Nordisk Inc | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: Biktarvy, DOVATO, ZEPBOUND, CABENUVA, PIFELTRO, Cologuard Collection Kit, VRAYLAR, Ozempic.
Industry payments across TX — which companies pay providers there.
